World's Best Scientists 2026 revealed!

D-Index & Metrics

Immunology

D-Index
50
Citations
11209
World Ranking
4215
National Ranking
15

Eun Bong Lee publication distribution in Immunology in 2026

The chart shows the distribution of publications by all Research.com ranked scientists in the field of Immunology in 2026. The highlighted bar marks where Eun Bong Lee sits on this spectrum.

62–71 publications: 9 scientists 72–81 publications: 23 scientists 82–91 publications: 40 scientists 92–101 publications: 72 scientists 102–111 publications: 86 scientists 112–121 publications: 108 scientists 122–131 publications: 150 scientists 132–141 publications: 160 scientists 142–151 publications: 159 scientists 152–161 publications: 189 scientists 162–171 publications: 166 scientists 172–181 publications: 181 scientists 182–191 publications: 188 scientists 192–201 publications: 187 scientists 202–211 publications: 178 scientists 212–221 publications: 158 scientists 222–231 publications: 168 scientists 232–241 publications: 159 scientists 242–251 publications: 160 scientists 252–261 publications: 148 scientists 262–271 publications: 116 scientists 272–281 publications: 125 scientists 282–291 publications: 115 scientists 292–301 publications: 111 scientists 302–311 publications: 95 scientists 312–321 publications: 97 scientists 322–331 publications: 97 scientists 332–341 publications: 99 scientists 342–351 publications: 96 scientists 352–361 publications: 68 scientists 362–371 publications: 76 scientists 372–381 publications: 71 scientists 382–391 publications: 71 scientists 392–401 publications: 62 scientists 402–411 publications: 54 scientists 412–421 publications: 41 scientists 422–431 publications: 63 scientists 432–441 publications: 53 scientists 442–451 publications: 31 scientists 452–461 publications: 42 scientists 462–471 publications: 40 scientists 472–481 publications: 29 scientists 482–491 publications: 34 scientists 492–501 publications: 30 scientists 502–511 publications: 23 scientists 512–521 publications: 41 scientists 522–531 publications: 29 scientists 532–541 publications: 28 scientists 542–551 publications: 16 scientists 552–561 publications: 18 scientists 562–571 publications: 18 scientists 572–581 publications: 17 scientists 582–591 publications: 17 scientists 592–601 publications: 17 scientists 602–611 publications: 19 scientists 612–621 publications: 13 scientists 622–631 publications: 12 scientists 632–641 publications: 11 scientists 642–651 publications: 16 scientists 652–661 publications: 9 scientists 662–671 publications: 5 scientists 672–681 publications: 13 scientists 682–691 publications: 12 scientists 692–701 publications: 6 scientists 702–711 publications: 6 scientists 712–721 publications: 9 scientists 722–731 publications: 9 scientists 732–741 publications: 6 scientists 742–751 publications: 11 scientists 752–761 publications: 10 scientists 762–771 publications: 7 scientists 772–781 publications: 12 scientists 782–791 publications: 7 scientists 792–801 publications: 5 scientists 802–806 publications: 1 scientists 807+ publications: 100 scientists
62 publications 807+

This scientist: 205 publications — 36th percentile

36% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 807 publications or more.

Eun Bong Lee D-index placement in Immunology in 2026

The chart shows the D-index (discipline H-index) distribution of Immunology scientists ranked by Research.com in 2026. The highlighted bar marks where Eun Bong Lee sits on this spectrum.

40–41 D-Index: 28 scientists 42–43 D-Index: 91 scientists 44–45 D-Index: 157 scientists 46–47 D-Index: 192 scientists 48–49 D-Index: 175 scientists 50–51 D-Index: 188 scientists 52–53 D-Index: 177 scientists 54–55 D-Index: 155 scientists 56–57 D-Index: 194 scientists 58–59 D-Index: 201 scientists 60–61 D-Index: 197 scientists 62–63 D-Index: 201 scientists 64–65 D-Index: 173 scientists 66–67 D-Index: 167 scientists 68–69 D-Index: 172 scientists 70–71 D-Index: 199 scientists 72–73 D-Index: 184 scientists 74–75 D-Index: 133 scientists 76–77 D-Index: 162 scientists 78–79 D-Index: 127 scientists 80–81 D-Index: 121 scientists 82–83 D-Index: 125 scientists 84–85 D-Index: 121 scientists 86–87 D-Index: 102 scientists 88–89 D-Index: 96 scientists 90–91 D-Index: 75 scientists 92–93 D-Index: 72 scientists 94–95 D-Index: 74 scientists 96–97 D-Index: 66 scientists 98–99 D-Index: 68 scientists 100–101 D-Index: 49 scientists 102–103 D-Index: 60 scientists 104–105 D-Index: 54 scientists 106–107 D-Index: 36 scientists 108–109 D-Index: 23 scientists 110–111 D-Index: 52 scientists 112–113 D-Index: 41 scientists 114–115 D-Index: 34 scientists 116–117 D-Index: 25 scientists 118–119 D-Index: 28 scientists 120–121 D-Index: 11 scientists 122–123 D-Index: 20 scientists 124–125 D-Index: 27 scientists 126–127 D-Index: 19 scientists 128–129 D-Index: 20 scientists 130–131 D-Index: 16 scientists 132–133 D-Index: 17 scientists 134–135 D-Index: 14 scientists 136–137 D-Index: 15 scientists 138–139 D-Index: 9 scientists 140–141 D-Index: 11 scientists 142–143 D-Index: 9 scientists 144–145 D-Index: 9 scientists 146–147 D-Index: 7 scientists 148–149 D-Index: 7 scientists 150–151 D-Index: 7 scientists 152–153 D-Index: 5 scientists 154–155 D-Index: 8 scientists 156 D-Index: 6 scientists 157+ D-Index: 96 scientists
40 D-Index 157+

This scientist: 50 D-Index — 15th percentile

15% of scientists in this discipline score the same or lower.

The last bar groups every scientist with 157 D-Index or more.

Overview

Eun Bong Lee is affiliated with Seoul National University Hospital in South Korea. Their research is principally situated in the field of Medicine with a focus on Rheumatology, Immunology, Epidemiology, Hematology, and Pathology and Forensic Medicine.

Their prominent topics of study include:

  • Rheumatoid Arthritis Research and Therapies
  • Systemic Lupus Erythematosus Research
  • Autoimmune and Inflammatory Disorders Research
  • Systemic Sclerosis and Related Diseases
  • Chronic Lymphocytic Leukemia Research
  • Tuberculosis Research and Epidemiology
  • Vasculitis and related conditions

Key recent papers by Eun Bong Lee include:

  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement, 2020, Annals of the Rheumatic Diseases
  • Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme, 2020, RMD Open
  • Systemic sclerosis and the COVID-19 pandemic: World Scleroderma Foundation preliminary advice for patient management, 2020, Annals of the Rheumatic Diseases
  • Primary Prophylaxis for Pneumocystis jirovecii Pneumonia in Patients Receiving Rituximab, 2021, CHEST Journal
  • COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology, 2021, Journal of Korean Medical Science

Frequent co-authors in their research include:

  • Jin Kyun Park
  • Yun Jong Lee
  • Eun Ha Kang
  • Jun Won Park
  • You-Jung Ha

Among the primary publication venues where Eun Bong Lee has contributed multiple papers are:

  • Arthritis & Rheumatology
  • Journal of Korean Medical Science
  • Scientific Reports
  • Annals of the Rheumatic Diseases
  • Arthritis Research & Therapy

Best Publications

  • Tofacitinib or adalimumab versus placebo in rheumatoid arthritis

    Ronald F. van Vollenhoven;Roy Fleischmann;Stanley Cohen;Eun Bong Lee

  • Phase IIb dose-ranging study of the oral JAK inhibitor tofacitinib (CP-690,550) or adalimumab monotherapy versus placebo in patients with active rheumatoid arthritis with an inadequate response to disease-modifying antirheumatic drugs.

    Roy Fleischmann;Maurizio Cutolo;Mark C. Genovese;Eun Bong Lee

  • Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials

    Stanley B. Cohen;Yoshiya Tanaka;Xavier Mariette;Jeffrey R. Curtis

  • Ixekizumab, an interleukin-17A antagonist in the treatment of ankylosing spondylitis or radiographic axial spondyloarthritis in patients previously untreated with biological disease-modifying anti-rheumatic drugs (COAST-V): 16 week results of a phase 3 randomised, double-blind, active-controlled and placebo-controlled trial

    Désirée van der Heijde;James Cheng-Chung Wei;Maxime Dougados;Philip Mease

  • Safety and efficacy of tofacitinib, an oral janus kinase inhibitor, for the treatment of rheumatoid arthritis in open-label, longterm extension studies.

    Jürgen Wollenhaupt;Joel Silverfield;Eun Bong Lee;Jeffrey R Curtis

  • Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial

    Gerd R Burmester;Yong Lin;Rahul Patel;Janet van Adelsberg

  • Safety and efficacy of tofacitinib for up to 9.5 years in the treatment of rheumatoid arthritis: final results of a global, open-label, long-term extension study

    Jürgen Wollenhaupt;Eun Bong Lee;Jeffrey R. Curtis;Joel Silverfield

  • Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement.

    Peter Nash;Andreas Kerschbaumer;Thomas Dörner;Maxime Dougados

  • Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: A randomised clinical trial

    Jin Kyun Park;Yun Jong Lee;Kichul Shin;You Jung Ha

  • The effect of tofacitinib on pneumococcal and influenza vaccine responses in rheumatoid arthritis

    Kevin L Winthrop;Joel Silverfield;Arthur Racewicz;Jeffrey Neal

  • Tofacitinib, an oral Janus kinase inhibitor: analysis of malignancies across the rheumatoid arthritis clinical development programme

    Jeffrey R Curtis;Eun Bong Lee;Irina V Kaplan;Kenneth Kwok

  • Mycobacterium tuberculosis infection in a corticosteroid-treated rheumatic disease patient population

    H. A. Kim;C. D. Yoo;H. J. Baek;Eun Bong Lee

  • Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

    Stanley B Cohen;Yoshiya Tanaka;Xavier Mariette;Jeffrey R Curtis

  • Effect of methotrexate discontinuation on efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial.

    Jin Kyun Park;Min Ah Lee;Eun Young Lee;Yeong Wook Song

  • Circulating exosomes from patients with systemic lupus erythematosus induce a proinflammatory immune response

    Joo Youn Lee;Jin Kyun Park;Jin Kyun Park;Eun Young Lee;Eun Bong Lee

  • Role of SLC7A5 in metabolic reprogramming of human monocyte/macrophage immune responses

    Bo Ruem Yoon;Yoon Jeong Oh;Seong Wook Kang;Eun Bong Lee

  • Abnormal distribution of Fcγ receptor type IIa polymorphisms in Korean patients with systemic lupus erythematosus

    Yeong Wook Song;Chang Wan Han;Seong Wook Kang;Han Joo Baek

  • Inhibitory effects of autoantibodies on the muscarinic receptors in Sjögren's syndrome.

    Jingchao Li;Young-Min Ha;Na-Youn Kü;Se-Young Choi

  • Effect of estrogen on the expression of matrix metalloproteinase (MMP)-1, MMP-3, and MMP-13 and tissue inhibitor of metalloproternase-1 in osteoarthritis chondrocytes.

    Yun Jong Lee;Eun Bong Lee;Young Ee Kwon;Jung Jin Lee

  • Myositis autoantibodies in Korean patients with inflammatory myositis: Anti-140-kDa polypeptide antibody is primarily associated with rapidly progressive interstitial lung disease independent of clinically amyopathic dermatomyositis

    Eun Ha Kang;Ran Nakashima;Tsuneyo Mimori;Jinhyun Kim

  • Imbalance of Th17 to Th1 cells in Behçet's disease

    Jinhyun Kim;Ji Ah Park;Eun Young Lee;Yun Jong Lee

  • Characterization of Effector Memory CD8+ T Cells in the Synovial Fluid of Rheumatoid Arthritis

    Bon A. Cho;Ji Hyun Sim;Ji Ah Park;Hye Won Kim

  • Tofacitinib or adalimumab versus placebo: patient-reported outcomes from a phase 3 study of active rheumatoid arthritis

    Vibeke Strand;Ronald F. van Vollenhoven;Eun Bong Lee;Roy Fleischmann

Frequent Co-Authors

Jeffrey R. Curtis
Jeffrey R. Curtis University of Alabama at Birmingham
Kevin L. Winthrop
Kevin L. Winthrop Oregon Health & Science University
Roy Fleischmann
Roy Fleischmann The University of Texas Southwestern Medical Center
Stanley Cohen
Stanley Cohen The University of Texas Southwestern Medical Center
Ronald F. van Vollenhoven
Ronald F. van Vollenhoven University of Amsterdam
Nobuhisa Mizuki
Nobuhisa Mizuki Yokohama City University
Shigeaki Ohno
Shigeaki Ohno Hokkaido University
Yoshiya Tanaka
Yoshiya Tanaka University of Occupational and Environmental Health Japan
Hidetoshi Inoko
Hidetoshi Inoko Tokai University
Masao Ota
Masao Ota Shinshu University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

For those interested in Immunology, pursuing a nursing degree can open diverse career pathways, including specialized roles in immunological research and patient care. Many students begin by exploring lpn programs with easiest admission requirements, offering a straightforward entry into healthcare. These programs provide foundational knowledge and clinical experience vital for immunology-related nursing roles.

Non-nurses aiming to switch careers can benefit from accelerated bsn programs for non nurses, which fast-track their education while catering to students without prior nursing background. This pathway allows quicker integration into nursing practice aligned with immunology specialties.

To further advance, nurses often consider best online rn programs for non nurses, which provide flexible learning environments and equip students with comprehensive skills for patient care, research, and collaboration in immunology contexts.

For those seeking leadership and clinical expertise, an accelerated np program serves as an ideal option. Nurse practitioners often work closely with immunologists, managing complex health conditions and contributing to innovative treatment strategies.

Best Scientists Citing Eun Bong Lee

Trending Scientists

Recently Published Articles